HOME >> BIOLOGY >> NEWS
Promising Fatty Acid Research Leads To MS Clinical Trial

Multiple Sclerosis (MS) is a common, disabling neurological disease of young adults. At the British Society for Immunology Annual Congress in Brighton this week, Laurence Harbige of the University of Greenwich and St Thomas' Hospital, London will present work on the effects of fatty acids in experimental models of MS.

Dr Harbige, working with colleagues at St Thomas' Hospital, has found that fatty acids from various plants and fungi can alter the course of the disease in animal models of MS. When fed these fatty acids, in a purified form, rodents with an experimental disease resembling MS did not develop disease.

MS is thought to be due to the body's immune system attacking our own tissue. In MS myelin, an insulating material surrounding nerve cells, is damaged. Dr Harbige and his colleagues think that certain fatty acids work by dampening down the damaging effects of the immune system.

The next stage is to find out whether the treatment will be effective in people with MS. MS patients have already been recruited for a double blind clinical trial to be conducted at St Thomas' Hospital starting early in the New Year.

Although encouraged by the experimental work, Dr Harbige warns against premature excitement over a treatment for people with MS, saying "further rigorous clinical and laboratory research is essential before we can recommend any such treatment for MS."

This research is supported by the Henry Smiths Charity. The Multiple Sclerosis Society has a help line for the general public to obtain further information on MS: 0171 371 8000.
'"/>

Contact: Dr Laurence Harbige
l.s.harbige@greenwich.ac.uk
+44 181 331 8485
British Society For Immunology
5-Dec-1997


Page: 1

Related biology news :

1. Promising hospital anti-infection strategy probably wont work, study shows
2. Promising research: From employment issues to virology
3. Promising new tool shows how dividing cells finish what they start
4. Promising biomarker for melanoma is identified
5. Promising multi-strain HIV vaccine candidate emerges
6. Promising new therapies for deadly form of leukemia
7. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
8. SFU Spin-Off Company To Research Promising Antibacterial Agents
9. SFU Molecular Biologist Pursues Promising New Way To Fight Disease
10. UNC-CH Researchers Develop Promising Heart Research Tool
11. Duke Researchers Call Gene Therapy A Promising Strategy For Sickle Cell Anemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to lead ... near term focus on Type 2 diabetes and associated comorbidities. , Justin brings ... areas and classes. As Chief Commercial Officer, Justin will lead Better Therapeutics’ ...
(Date:7/18/2020)... SAN ANTONIO (PRWEB) , ... July 16, 2020 ... ... PLOS ONE that demonstrates the effectiveness of the Invictus Medical Neoasis™ active noise ... (NICU) environment. The study reported that the Neoasis™ device attenuated the alarm sounds ...
(Date:7/10/2020)... ... July 08, 2020 , ... Overcoming ... Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. ... what is the most effective way to complete one? Will the study comply ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... ... leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... have entered into a strategic partnership whereby Catalent will provide support for the ...
(Date:7/18/2020)... ... ... After research model surgery and catheter implantation, the long journey of catheter maintenance and ... successful study, while protecting and accessing the catheter or device post-surgery is often undervalued ... Envigo in a live webinar on Wednesday, August 5, 2020 at ...
(Date:7/10/2020)... (PRWEB) , ... July 09, ... ... biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded ... broader license allows PathSensors to move into the point-of-care diagnostic market, focusing ...
(Date:7/1/2020)... CHARLOTTE, N.C. (PRWEB) , ... June 29, 2020 ... ... has reported year to date growth of 40% in 2020, despite many obstacles ... medical technology, MedShift aims to increase revenue for its partnered medical practices and ...
Breaking Biology Technology:
Cached News: